Australia markets close in 5 hours 33 minutes

Stoke Therapeutics, Inc. (STOK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.5600-0.0200 (-0.56%)
At close: 04:00PM EDT
3.5600 0.00 (0.00%)
After hours: 05:04PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.5800
Open3.5700
Bid3.3800 x 800
Ask3.7600 x 1200
Day's range3.3700 - 3.5900
52-week range3.3700 - 16.4800
Volume394,974
Avg. volume401,989
Market cap157.683M
Beta (5Y monthly)0.34
PE ratio (TTM)N/A
EPS (TTM)-2.3100
Earnings date13 Nov 2023 - 17 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est20.75
  • Business Wire

    Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

    BEDFORD, Mass., September 21, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will participate in a panel presentation at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET.

  • Business Wire

    Stoke Therapeutics Appoints Ian Smith to its Board of Directors

    BEDFORD, Mass., September 20, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19.

  • Business Wire

    Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress

    DUBLIN, September 05, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations related to the ongoing clinical development of STK-001, the first potential new medicine to treat the underlying cause of Dravet syndrome. Four posters from the Company’s work in Dravet syndrome are being presented at the International